Ian Clark

Ian Clark joined the board of directors of Gyroscope Therapeutics in 2019. Ian has more than 34 years of experience in the biotechnology and pharmaceutical industry, most recently serving as CEO and member of the board of directors for Genentech, a member of the Roche Group, until his retirement in 2016. During his seven-year tenure as CEO, Ian and his team brought eleven new medicines to market for patients fighting rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Ian was among the highest rated CEOs by Glassdoor, recognized as the Bay Area’s most admired CEO by the San Francisco Business Times and awarded the Honorable Mentor of the Year by the Heath Business Woman’s Association.

Prior to joining Genentech, Ian held various positions of increasing responsibility at Novartis, Sanofi, Ivax and Searle, working in the USA, UK, Canada, Eastern Europe and France.

Currently, Ian is on the board of directors for Takeda, Agios Pharmaceuticals, Guardant Health, Forty Seven, Avrobio and Corvus Pharmaceuticals. He is an Operating Partner of Blackstone Life Sciences. He is also on the BioFulcrum Board of the Gladsone Institute. Ian previously served on the board of directors of Shire, Kite Pharma, Dendreon, Solazyme and Vernalis. He was also on the Biotechnology Industry Association board of directors and on the Economic Advisory Council of the 12th District of the Federal Reserve.

Ian received his bachelor of science in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom.